Wall Street brokerages expect that Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) will announce earnings of ($0.59) per share for the current quarter, according to Zacks. Five analysts have issued estimates for Momenta Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.47) and the lowest estimate coming in at ($0.81). Momenta Pharmaceuticals reported earnings per share of ($0.07) during the same quarter last year, which indicates a negative year-over-year growth rate of 742.9%. The company is scheduled to issue its next quarterly earnings report on Friday, February 28th.

According to Zacks, analysts expect that Momenta Pharmaceuticals will report full-year earnings of ($2.58) per share for the current fiscal year, with EPS estimates ranging from ($2.88) to ($2.10). For the next financial year, analysts expect that the business will report earnings of ($2.10) per share, with EPS estimates ranging from ($2.51) to ($1.74). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Momenta Pharmaceuticals.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.09). Momenta Pharmaceuticals had a negative net margin of 361.66% and a negative return on equity of 59.82%. The firm had revenue of $6.40 million for the quarter, compared to analyst estimates of $5.24 million. During the same period in the previous year, the business posted ($0.65) earnings per share. Momenta Pharmaceuticals’s revenue for the quarter was down 57.0% on a year-over-year basis.

MNTA has been the subject of several recent analyst reports. Wells Fargo & Co started coverage on Momenta Pharmaceuticals in a research note on Wednesday, November 6th. They set an “outperform” rating for the company. ValuEngine upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. HC Wainwright began coverage on Momenta Pharmaceuticals in a report on Wednesday, September 25th. They issued a “buy” rating and a $24.00 price target for the company. BidaskClub downgraded Momenta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 19th. Finally, Piper Jaffray Companies set a $35.00 price objective on Momenta Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, September 17th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $23.45.

Shares of MNTA stock opened at $16.61 on Friday. Momenta Pharmaceuticals has a 12 month low of $9.51 and a 12 month high of $17.56. The firm has a market capitalization of $1.66 billion, a P/E ratio of -8.18 and a beta of 2.07. The company’s fifty day moving average price is $15.50 and its two-hundred day moving average price is $13.04.

In other news, SVP Santiago Arroyo sold 6,318 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $13.83, for a total value of $87,377.94. Following the completion of the sale, the senior vice president now owns 33,272 shares of the company’s stock, valued at approximately $460,151.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Craig A. Wheeler sold 66,666 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $17.00, for a total transaction of $1,133,322.00. Following the completion of the sale, the chief executive officer now owns 79,343 shares in the company, valued at approximately $1,348,831. The disclosure for this sale can be found here. Insiders have sold a total of 143,928 shares of company stock worth $2,305,814 over the last quarter. 3.40% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of the stock. Metropolitan Life Insurance Co NY lifted its holdings in Momenta Pharmaceuticals by 1.9% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 32,021 shares of the biotechnology company’s stock worth $415,000 after buying an additional 596 shares during the last quarter. Arizona State Retirement System raised its position in shares of Momenta Pharmaceuticals by 0.7% during the 2nd quarter. Arizona State Retirement System now owns 152,967 shares of the biotechnology company’s stock valued at $1,904,000 after acquiring an additional 1,003 shares in the last quarter. United Services Automobile Association raised its position in shares of Momenta Pharmaceuticals by 0.9% during the 2nd quarter. United Services Automobile Association now owns 218,633 shares of the biotechnology company’s stock valued at $2,722,000 after acquiring an additional 1,890 shares in the last quarter. CWM Advisors LLC raised its position in shares of Momenta Pharmaceuticals by 17.2% during the 2nd quarter. CWM Advisors LLC now owns 13,780 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 2,020 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its stake in Momenta Pharmaceuticals by 5.6% during the second quarter. Oregon Public Employees Retirement Fund now owns 39,254 shares of the biotechnology company’s stock worth $489,000 after purchasing an additional 2,074 shares during the last quarter. Institutional investors and hedge funds own 97.04% of the company’s stock.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

See Also: Why is insider trading harmful?

Get a free copy of the Zacks research report on Momenta Pharmaceuticals (MNTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.